We have assembled an experienced management team with deep expertise in oncology, immunology, clinical and regulatory development. Our business leaders and scientific advisors bring all the skills and experience from world-leading organizations to deliver novel immunotherapies

Management Team

Borys Shor, PhD

President & CEO

John Psaltos, MBA, CPA

Chief Financial Officer

John Mohr, CPA

VP, Commercial & Licensing

William Johnson

VP, Corporate Development

Agnes Westelink, Pharm.D

VP, Regulatory Strategy

Ralph Kauten, MBA

Business Advisor

Board Of Directors

Borys Shor, PhD

Chairman of the Board

Robert Easton, MBA


Ronald T. Raines, PhD


Scientific Advisory Board
Biologic Therapies

Dhaval Shah, Ph.D.

Scientific Advisor

Associate Professor, Pharmaceutical Sciences,
University at Buffalo, New York

Nathan Tumey, Ph.D

Scientific Advisor
Antibody Drug Conjugates

Associate Professor, Pharmaceutical Sciences,
Binghamton University, New York

Jean Kadouche, Ph.D

Scientific Advisor
Antibody Development

INSERM, Saint-Louis Hospital & Européen Georges Pompidou Hospital in Paris

Microbial Immunity

Yossef Av-Gay, Ph.D.

Scientific Co-Founder
Microbiology and Immunology

Full Professor, Division Of Infectious Diseases,
The University of British Columbia

Jessica Seeliger, Ph.D.

Scientific Advisor
Microbial Biochemistry

Associate Professor, Pharmacological Sciences,
Stony Brook University, New York

Claudia Gravekamp, Ph.D

Scientific Advisor

Associate Professor, Microbiology & Immunology,
Albert Einstein College Of Medicine, New York

Dr. Shor has over 20 years of experience in leading oncology discovery programs and external R&D partnerships at large pharmas (Wyeth, Pfizer) and biotech companies, with specific focus on preclinical discovery and development of biologics, small molecule kinase inhibitors and nanoparticles. He is a founder and the CEO of Manhattan BioSolutions Inc. Dr. Shor also serves as a BioEntrepreneur-In-Residence with the New York State Biotechnology Center in Long Island and is a founder of Bioidea Group, a biotech consultancy in New York City. Previously at Pfizer, Borys led cross-functional oncology research teams to develop novel antibody-drug conjugates and supported Biological License Application (BLA) filing for Inotuzumab, which was approved for the treatment of leukemia in 2017. Prior to that, Dr. Shor served as a project team leader at the department of Oncology Discovery at Wyeth Pharmaceuticals, managing the discovery and characterization of novel mTOR/PI3K kinase inhibitors for the treatment of cancer.

Dr Shor earned M.S. degree in molecular genetics from the St. Petersburg State University. He also received a Ph.D. in Molecular and Cell Biology at the SUNY Downstate Medical Center and performed a postdoctoral fellowship in the Inflammation Research team at Johnson & Johnson Pharmaceutical R&D prior to joining Wyeth

John Psaltos is an outstanding senior financial professional with over 20 years of experience in accounting, financial operations, strategic and business planning, reporting and financial systems implementation. John is experienced in biopharmaceutical R&D and manufacturing and has a long track record of supervising, inspiring, and mentoring team members to reach professional goals and deliverables. He is self-motivated and results-oriented, skillfully propelling his clients towards success and financial stability. John’s financial leadership is demonstrated through his previous work at Archstone Advisory Group as an Interim CFO who provided the company with accounting, tax, and finance advisory services. He has worked with companies from a variety of fields, including biotech, real estate, aquaculture, manufacturing, distribution, and non-profit and e-commerce industries. John planned and implemented a capital fundraising campaign, raising $1 million in Seed Round financing, prepared monthly financial statements and KPI tracking, established forecasting and budgeting models and procedures, and designed and implemented financial systems and controls. His talent and expertise are instrumental helping companies achieve financial control and stability.

Mr. Mohr is a multidimensional drug industry consultant and former executive with expertise in managing emerging company issues.  His distinguished career includes management of multi-million dollar brands and building products from ‘bench-to-market’.  Prior to co-founded BioAsset Advisors, Mr. Mohr led Business and Corporate Development at CV Therapeutics leading to a major licensing deal and subsequent $1.4 billion M&A transaction with Gilead. Mr. Mohr possesses a portfolio of worldwide contacts and provides significant experience closing successful licensing and M&A transactions. His experience includes President of Fournier Pharma, responsible for operations including clinical development, regulatory, and business development activities.  He built a strategic partnership with Abbott for TriCor®/ Trilipix, a $1.5 billion cardiovascular brand. While at Merck, he led Financial Services for North America operations, followed by six years of responsibility for Marketing and New Product Planning, including worldwide marketing franchise head for the blockbuster brand Pepcid®. Mr. Mohr is a CPA and a graduate of Drexel University with a BS in Finance & Accounting.

Bob has been recognized as a thought leader in medical business strategy for almost forty years. Bob was formerly co-chairman of Bionest Partners. Prior to that, he built and led two other consulting firms, The Wilkerson Group and Easton Associates. Bob has led strategy development and supervised opportunity assessments for hundreds of clients on four continents, including large and specialty pharmaceutical companies, early-stage through publicly-traded biopharmaceutical companies, and diagnostics businesses. He is past chairman of the New York Biotechnology Association and has served on ten medical company boards. He also serves as past chairman of Gilda’s Club of New York City. Bob holds degrees in chemical engineering from Rice University and an MBA from the Harvard Business School.

Ronald T. Raines is the Firmenich Professor of Chemistry at the Massachusetts Institute of Technology and Professor Emeritus at the University of Wisconsin–Madison. He was born in Montclair, New Jersey, and received Sc.B. degrees in chemistry and biology at MIT, performing undergraduate research with Christopher T. Walsh. Raines received A.M. and Ph.D. degrees in chemistry at Harvard University for research done with Jeremy R. Knowles. He was a Helen Hay Whitney postdoctoral fellow with William J. Rutter (1962 Guggenheim Fellow) in the Department of Biochemistry and Biophysics at the University of California, San Francisco. Raines then joined the faculty at the University of Wisconsin–Madison, where he became the Henry Lardy Professor of Biochemistry, Linus Pauling Professor of Chemical Biology, and a Professor of Chemistry. He was a Visiting Associate at Caltech in 2009. In 2017, he returned to MIT.

Raines is an expert on the chemical basis for protein structure and function. His efforts have led to an RNA-cleaving enzyme that is in a multi-site human clinical trial as an anti-cancer agent, revealed that unappreciated forces—the n-to-pi* interaction and C5 hydrogen bond—stabilize all proteins, created hyperstable and human-scale synthetic collagens; and developed processes to synthesize proteins, catalyze their folding, and facilitate their entry into human cells, and to convert crude biomass into useful fuels and chemicals. He is an author of over 500 papers and abstracts, delivered over 300 invited lectures in over 25 countries, and supervised over 50 doctoral theses. He holds over 50 U.S. patents, and co-founded Quintessence Biosciences, Inc. (as a 2001 Guggenheim Fellow), Hyrax Energy, Inc., and Ghost Proteins, Inc., which are developing inventions from his laboratory.

Powered by